A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in combination with gemcitabine to patients with advanced pancreatic cancer.
Pancreatic Cancer
DRUG: CP-675,206 and gemcitabine
Dose Limiting Toxicities: assessed through adverse event data collected weekly, 8 week intervals
HAHA Response to CP-675,206:, 12 months|Lymphocyte Subset Analysis:, 12 months|Cytokine Analysis:, 12 months|Pharmacogenomic Analysis:, 1 month|Overall Survival:, 12 months|Pharmacokinetics of CP-675,206 and Gemcitabine:, 2 months|Best Overall Response:, 3 months|Duration of Tumor Response:, 3 months|Progression-Free Survival:, 5 months
The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in combination with gemcitabine to patients with advanced pancreatic cancer.